Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd (PRFX) is a clinical-stage pharmaceutical innovator developing advanced pain management solutions through therapeutic reformulation. This page aggregates official announcements, clinical trial updates, and strategic developments related to the company’s extended-release drug-delivery platform.
Investors and healthcare professionals will find timely updates on PRF-110’s progress through FDA pathways, postoperative analgesia research, and operational milestones. The curated news collection serves as a centralized resource for tracking the company’s unique approach to reducing opioid reliance via localized, sustained pain relief therapies.
Key content categories include clinical trial results, regulatory filings, partnership announcements, and scientific presentations. All materials are sourced from verified channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to PainReform’s latest developments in drug reformulation technology and its evolving position within the specialty pharmaceuticals sector.
PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Dawson James Securities Small Cap Growth Conference on October 21, 2021, at 3:15 PM ET in Jupiter, Florida. This conference will feature one-on-one meetings with qualified investors. The live webcast and recorded presentation will be accessible on PainReform's investor relations website. PainReform specializes in reformulating therapeutics, focusing on PRF-110, which targets post-operative pain relief through an innovative drug-delivery system.
PainReform Ltd. (NASDAQ: PRFX) announced a shift of manufacturing operations for its lead product, PRF-110, to a U.S.-based Contract Development and Manufacturing Organization to enhance quality and efficiency. This decision aims to resolve previous manufacturing delays, with plans to initiate Phase 3 clinical trials by Q1 2022. As of June 30, 2021, PainReform reported $17.8 million in cash, which increased to over $19 million following recent warrant exercises. The company also reported a net loss of $3.7 million for the first half of 2021, up from $2.0 million a year earlier.
PainReform Ltd. (Nasdaq: PRFX) reported significant advancements towards launching Phase 3 clinical trials for PRF-110, targeting post-operative pain relief in bunionectomy surgery. With a strong cash position of $19.4 million as of March 31, 2021, the company is prepared for ongoing activities and future trials. Recent financial results show a net loss of $2.041 million for Q1 2021, reflecting a 57% increase from the previous year due to rising operational costs linked to clinical trial preparations. The firm remains optimistic about PRF-110's potential to reduce opioid reliance.
PainReform Ltd. (Nasdaq: PRFX) announced significant progress in its Phase 3 clinical trials for PRF-110. The company engaged Lotus Clinical Research for the bunionectomy surgery trial, set to begin mid-2021. Recent achievements include a $6 million private placement, enhancing its cash runway for key milestones. However, the company reported a net loss of $4.1 million for 2020, with substantial increases in R&D and administrative expenses. The cash position as of December 31, 2020, was $15.7 million, expected to fund operations into Q2 2022.
PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. This presentation will be accessible to registered participants and later posted on PainReform’s website. The company specializes in reformulating established therapeutics, with its lead product, PRF-110, focusing on post-operative pain relief using a local anesthetic, ropivacaine. PRF-110 aims to provide extended analgesia through a unique delivery system, reducing the need for opiates.
PainReform Ltd. (Nasdaq: PRFX) announced a private placement to raise approximately $6.0 million by issuing 1,304,346 ordinary shares and warrants. The purchase price is set at $4.60 per share, with warrants allowing the purchase of an additional 652,173 shares. Closing is expected on March 10, 2021, pending customary conditions. Maxim Group LLC and Joseph Gunnar & Co., LLC are acting as placement agents. The securities will not be registered under the Securities Act and are offered only to accredited investors. This move highlights PainReform's strategy to secure funding for its pain relief product, PRF-110.
PainReform Ltd. (Nasdaq: PRFX), a clinical stage specialty pharmaceutical company, announced participation in the H.C. Wainwright BioConnect 2021 Conference, occurring virtually from January 11-14, 2021. A webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 a.m. ET, accessible for 90 days. PainReform's lead product, PRF-110, aims to enhance post-operative pain relief using a proprietary extended-release drug-delivery system, targeting the local anesthetic market with reduced opiate needs.
PainReform Ltd. (Nasdaq: PRFX) has appointed Rita Keynan as Vice President of Pharmaceutical Operations. With over 25 years in the pharmaceutical sector, Keynan has a solid background in drug development, overseeing all facets from early trials to NDA filings. Her prior role was with VYNE Therapeutics, managing a team focused on drug development. CEO Ilan Hadar expressed confidence in her capabilities as the company prepares for Phase 3 trials of their lead product, PRF-110, aimed at post-operative pain relief through an innovative drug-delivery system.
PainReform Ltd. (NasdaqCM:PRFX) announced the appointment of Lotus Clinical Research as its CRO for the upcoming Phase 3 trial of PRF-110. This trial will focus on patients undergoing bunionectomy and hernia repair operations. LCR is specialized in analgesic studies, with a history of approximately 350 trials resulting in over ten approvals. Previous Phase 2 results showed PRF-110 provided pain relief for up to 72 hours, outperforming ropivacaine's 2-6 hours. The CEO stated confidence in the trial's design, aiming to address the opioid crisis while demonstrating safer pain relief options.
PainReform Ltd. (NASDAQ:PRFX) has appointed Ilan Hadar as its new CEO, effective immediately. With over 20 years in the pharmaceutical sector, Hadar has led operations and developed products in the U.S. and Israel. His previous roles include serving as Country Manager and CFO at Foamix Pharmaceuticals and Finance Director at Pfizer. The appointment comes as PainReform prepares for pivotal Phase 3 trials for its lead product PRF-110, aimed at changing post-operative pain management by reducing reliance on opioids.